Abbott Laboratories Corporation

Abbvie Inc.

Tianyuan Zhang

Todd M Hansen

Richard F Clark

Hing L Sham

Moshe Weitzberg

Bruce A Beutel

Gang Liu

Philip R Kym

Rolf Wagner

Zhili Xin

Zhenkun Ma

Rajesh R Iyengar

Michael D Tufano

Hong Yong

Andrew S Judd

Christopher E Motter

Qun Li

Curt S Cooper

Douglas M Kalvin

David D Anderson

Gang Zhao

Heidi S Camp

Xiangdong Xu

Yu Gui Gu

Robert F Keyes

William Sanders

Mira Hinman

Teresa A Rosenberg

Yu-Gui Gu

Daniel P Larson

Hongyu Zhao

Linda M Lynch

Todd D Bosse

Mei Liu

Peter Dandliker

Caroline David

Fabio Palazzo

Yugui Gu

Ernst U Frevert

Barbara L Cool

Xiaojun Wang

Tamara Rehm

The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome

Antibacterials having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

Antibacterial compounds

The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.

Thienopyridones as AMPK activators for the treatment of diabetes and obesity

Growing community of inventors

Gurnee, IL, United States of America

Tianyuan Zhang